跳至主要内容
临床试验/CTRI/2021/01/030334
CTRI/2021/01/030334招募中2 期

A study to assess the safety and efficacy of Hypo-fractionated Intensity modulated Radiation Therapy with Simultaneous Integrated Boost Technique along with Concurrent and Adjuvant chemotherapy with Temozolomide in newly diagnosed, biopsy proven patients with Glioblastoma. - HISCAT

Christian Medical College Vellore0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a. Histologically proven Glioblastoma
  • b. Age 18-70
  • c. Karanofsky Performance score >70
  • d. Surgery done within 4 weeks prior to enrollment.
  • e. Haematological parameters
  • 1.Haemoglobin >10 gm /dL
  • 2.Absolute Neutrophil Count >1500 cell /cu mm
  • 3.Platelet count > 1 ,00,000
  • f. Liver Enzymes (SGOT , SGPT) < 3 times the upper limit of normal
  • g. Serum Bilirubin < 5 times the upper limit of normal
  • h. Serum Creatnine < 3 times the upper limit of normal

排除标准

  • a. Multifocal disease
  • b. Unresectable patients
  • c. Previous history of Radiation Therapy
  • d. Not willing for followup

研究者

发起方
Christian Medical College Vellore

相似试验